Serum Cystatin C Predicts Mortality in HBV-Related Decompensated Cirrhosis
Table 1
Baseline clinical and laboratory characteristics of the study population.
HBV-DeCi patients (n=75)
Gender (male/female)
59/16
Age (y)
53.0±11.0
Total protein (g/L)
58.8±8.1
Albumin (g/L)
28.0±5.2
ALT (U/L)
38.0(23.0–66.0)
AST (U/L)
56.0(60.0–87.0)
Total bilirubin (μmol/L)
96.0(61.0–203.0)
INR
1.60±0.39
Serum Cr (mmol/L)
72.0(60.0–99.0)
HBsAg, positive
75
HBeAg, positive
44
HBcAb IgM, positive
0
Cystatin C (mg/L)
1.06(0.90–1.48)
MELD score
17.4(13.7–21.4)
Child-Pugh score
10.0(9.0–11.0)
Modes of decompensation
10.0(9.0–11.0)
HE, n (%)
2(2.7%)
HRS, n (%)
5(6.7%)
Ascites, n (%)
48(64.0%)
Variceal bleeding, n (%)
22 (29.3%)
Data are expressed as n, mean ± SD, or median (interquartile range). ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; Cr, creatinine; HE, hepatic encephalopathy; HRS, hepatorenal syndrome; MELD score, model for end-stage liver disease score.